Ingested (oral) SST inhibits EAE

References

• Alvord EC, Shaw CM, Huby S, Kies MK. Encephalitogen-induced inhibition of experimental allergic encephalomyelitis: Prevention, suppression, and therapy. Ann N Y Acad Sci. 1965; 122:333–345.
   PubMed Web of Science ®Google Scholar
• Raine CS, Stone SH. Animal models for multiple sclerosis: Chronic experimental allergic encephalomyelitis in inbred guinea pigs. N Y State J Med. 1977; 77:1693–1696.
   Google Scholar
• Wisnewski HM, Keith AB. Chronic relapsing experimental allergic encephalomyelitis: An experimental model of multiple sclerosis. Ann Neurol. 1977; 1:144–148.
   Google Scholar
• Feuer C, Prentice DE, Cammisuli S. Chronic relapsing experimental allergic encephalomyelitis in the lewis rat. J Neuroimmunol. 1985; 10:159–166.
   Google Scholar
• Brod SA, Burns DK. Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons. Neurology. 1994; 44:1144–1148.
   Google Scholar
• Brod SA, Hood Z. Ingested (oral) SIRS peptide 1-21 inhibits acute EAE by inducing Th(2)-like cytokines. J Neuroimmunol. 2007; 183:89–95.
   Google Scholar
• Brod SA, Hood ZM. Ingested (oral) alpha-MSH inhibits acute EAE. J Neuroimmunol. 2008; 193:106–112.
   Google Scholar
• Brod SA, Khan M, Kerman RH, Pappolla M. Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. J Neuroimmunol. 1995; 58:61–69.
   Google Scholar
• Brod SA, Khan M. Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis. J Autoimmun. 1996; 9:11–20.
   PubMed Web of Science ®Google Scholar
• Ferone D, Boschetti M, Resmini E, Giusti M, Albanese V, Goglia U, Albertelli M, Vera L, Bianchi F, Minuto F. Neuroendocrine-immune interactions: The role of cortistatin/somatostatin system. Ann N Y Acad Sci. 2006; 1069:129–144.
   PubMed Web of Science ®Google Scholar
• Ferone D, Resmini E, Boschetti M, Arvigo M, Albanese V, Ceresola E, Pivonello R, Albertelli M, Bianchi F, Giusti M, Minuto F. Potential indications for somatostatin analogues: Immune system and limphoproliferative disorders. J Endocrinol Invest. 2005; 28:111–117.
   Google Scholar
• ten Bokum AM, Hofland LJ, van Hagen PM. Somatostatin and somatostatin receptors in the immune system: A review. Eur Cytokine Netw. 2000; 11:161–176.
   PubMed Web of Science ®Google Scholar
• Tompkins SM, Padilla J, Dal Canto MC, Ting JP, Van Kaer L, Miller SD. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. J Immunol. 2002; 168:4173–4183.
   PubMed Web of Science ®Google Scholar
• Dong C. Diversification of T-helper-cell lineages: Finding the family root of IL-17-producing cells. Nat Rev Immunol. 2006; 6:329–333.
   PubMed Web of Science ®Google Scholar
• Gaffen SL, Kramer JM, Yu JJ, Shen F. The IL-17 cytokine family. Vitam Horm. 2006; 74:255–282.
   PubMed Web of Science ®Google Scholar
• De Carli M, D'Elios MM, Zancuoghi G, Romagnani S, Del Prete G. Human Th1 and Th2 cells: Functional properties, regulation of development and role in autoimmunity. Autoimmunity. 1994; 18:301–308.
   PubMedGoogle Scholar
• Kroemer G, Hirsch F, Gonzalez-Garcia A, Martinez C. Differential involvement of Th1 and Th2 cytokines in autoimmune diseases. Autoimmunity. 1996; 24:25–33.
   PubMed Web of Science ®Google Scholar
• Brod SA, Khan M, Nelson LD, Decuir B, Malone M, Henninger E. Adoptive transfer from interferon-alpha-fed mice is associated with inhibition of active experimental autoimmune encephalomyelitis by decreasing recipient tumor necrosis factor-alpha secretion. J Immunother. 2000; 23:235–245.
   Google Scholar
• Malefyt R, Haanen J, Spits H, Roncarolo M-G, te Velde A, Figdor CG, de Vries JE. IL-10 and viral IL-10 strongly reduce antigen specific human T-cell proliferation by diminishing the antigen presenting capacity of monocytes via downregulation of class II MHC expression. J Exp Med. 1991; 174:915–924.
   PubMed Web of Science ®Google Scholar
• Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, Freeman GJ, Kuchroo VK. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002; 415:536–541.
   PubMed Web of Science ®Google Scholar
• Yu P, Gregg RK, Bell JJ, Ellis JS, Divekar R, Lee HH, Jain R, Waldner H, Hardaway JC, Collins M, Kuchroo VK, Zaghouani H. Specific T regulatory cells display broad suppressive functions against experimental allergic encephalomyelitis upon activation with cognate antigen. J Immunol. 2005; 174:6772–6780.
   PubMed Web of Science ®Google Scholar
• Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, Delignat S, Elluru S, Bayry J, Lacroix-Desmazes S, Cohen JL, Salomon BL, Kazatchkine MD, Kaveri SV, Misra N. Expansion of CD4+ CD25+ regulatory T cells by intravenous immunoglobulin: A critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008; 111:715–722.
   PubMed Web of Science ®Google Scholar
• Kohm AP, Carpentier PA, Miller SD. Regulation of experimental autoimmune encephalomyelitis (EAE) by CD4+ CD25+ regulatory T cells. Novartis Found Symp. 2003; 252:45–52 discussion -4, 106–114.
   PubMedGoogle Scholar
• Sun D, Whitaker JN, Wilson DB. Regulatory T cells in experimental allergic encephalomyelitis. I. Frequency and specificity analysis in normal and immune rats of a T cell subset that inhibits disease. Int Immunol. 1999; 11:307–315.
   Google Scholar
• Matsumoto Y, Sakuma H, Kohyama K, Park IK. Paralysis of CD4(+)CD25(+) regulatory T cell response in chronic autoimmune encephalomyelitis. J Neuroimmunol. 2007; 187:44–54.
   PubMed Web of Science ®Google Scholar
• Lavasani S, Dzhambazov B, Nouri M, Fak F, Buske S, Molin G, Thorlacius H, Alenfall J, Jeppsson B, Westrom B. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One. 2010; 5:e9009.
   PubMed Web of Science ®Google Scholar
• Lichtenauer-Kaligis EG, van Hagen PM, Lamberts SW, Hofland LJ. Somatostatin receptor subtypes in human immune cells. Eur J Endocrinol. 2000; 143 Suppl 1: S21–S25.
   Google Scholar
• ten Bokum AM, Lichtenauer-Kaligis EG, Melief MJ, van Koetsveld PM, Bruns C, van Hagen PM, Hofland LJ, Lamberts SW, Hazenberg MP. Somatostatin receptor subtype expression in cells of the rat immune system during adjuvant arthritis. J Endocrinol. 1999; 161:167–175.
   Google Scholar
• Levite M. Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. Proc Natl Acad Sci USA. 1998; 95:12544–12549.
   PubMed Web of Science ®Google Scholar
• Adorini L, Guery JC, Trembleau S. Manipulation of the Th1/Th2 cell balance: An approach to treat human autoimmune diseases?. Autoimmunity. 1996; 23:53–68.
   PubMed Web of Science ®Google Scholar